Results 221 to 230 of about 157,060 (341)

Ultrasound and MRI abdominal fat distribution and its associations with metabolic conditions in adults with abdominal obesity

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the accuracy of abdominal fat distribution of subcutaneous (SAT) and visceral adipose tissue (VAT) assessed by ultrasound (US) compared to magnetic resonance imaging (MRI), as the gold standard technique. Additionally, to assess the association between abdominal fat distribution measured by US and metabolic conditions in ...
Claudia Jiménez‐ten Hoevel, Maria Besora‐Moreno, Judit Queral, Elisabet Llauradó, Rosa M. Valls, Rosa Solà, Anna Pedret   +6 more
wiley   +1 more source

Systematic review of Mendelian randomization studies on antihypertensive drugs. [PDF]

BMC Med
Fan B, Zhang J, Zhao JV.
europepmc   +1 more source

Profile Of Antihypertensive Drug Use In Patients With Coronary Artery Disease At Prof. Dr. I.G.N.G. Ngoerah General Hospital (RSUP) In 2023

Jainal Arifin, Ida Ayu Alit Widhiartini, I Made Jawi   +2 more
openalex   +1 more source

New Easily Swallowed Tablets with Slippery Coating for the Antihypertensive Drug Valsartan

, 2015
Zainab H. Mahdi, Nidhal K. Maraie
openalex   +2 more sources

Change in body mass index and disease burden among people with obesity and multiple long‐term conditions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a risk factor for multiple long‐term conditions (MLTCs/multimorbidity). However, the impact of weight loss in people with MLTCs is unclear. We investigated the association between body mass index (BMI) change and the development of obesity‐related complications (ORCs), as well as clinical and economic outcomes in individuals ...
Kamlesh Khunti, Alex Mourer, Silvia Capucci, Lua Wilkinson, Klaus K. Andersen, Abd A. Tahrani, Camilla S. Morgen   +6 more
wiley   +1 more source

Molecular basis of domain-specific angiotensin I-converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat. [PDF]

FEBS J
Gregory KS, Ramasamy V, Sturrock ED, Acharya KR.   +3 more
europepmc   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

LASSO logistic regression and cluster analysis in predicting adherence and drug patterns among new users of monotherapy for antihypertensive drugs. [PDF]

J Hypertens
Li X, Tia MD, Bos JHJ, Schuiling-Veninga CCM, Hak E, Mubarik S.   +5 more
europepmc   +1 more source

Antihypertensive medication is not associated with increased disease severity in atopic dermatitis in the TREATgermany registry

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Moritz M. Hollstein, Stephan Traidl, Thomas Werfel, Jochen Schmitt, the TREATgermany Study Group   +4 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source